Along with suspending financial guidance, the company should suspend the ceo and bod salaries.
M
Addex ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy Thu Jan 21 07:02:03 2021 EDT First patient treated with ADX71149 (JNJ-40411813) scheduled for Q2 2021 Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that its partner Janssen Pharmaceuticals, Inc. , part of the Janssen Pharmaceutical Companies of Johnson & Johnson , has received FDA’s Investigational New Drug (IND) approval to begin a Phase 2a proof of concept study with the selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM), JNJ-40411813 (ADX71149), in patients with epilepsy. The first patient is expected to be treated during Q2 2021.
Pre Market Resistance at 18.20 - then there is little resistance upwards.
S
$ADXN ADXN.S.W TICKER CHF SWISS THIS IS THERE PHARMACEUTICAL STOCK ITS ROCKETING TODAY thats the ticker its there pharmaceutical side look at it already jumped 20%
P
Nobody seems to care about this company. Under the radar is an understatement. I am accumulating. Join me for some fun. We can go to Switzerland for the next annual meeting. Beautiful place, I've been there. I see this as a takeover candidate because of their deep pipeline. If there are people that disagree, please post yoir opinion. I am always looking to reevaluate based on new info.
l
This is my first operation in ADXN and I won... Now seem I have to pay taxes to take out the money. Can someone explain me if this is true?
Bullish
P
There are a whole lot of ADXN "catalysts" (I hate that word) either imminent or scheduled for Q2. Epilepsy, Parkinson's, twitchy eyelids (don't laugh, that can be a big problem). I think now is a good price and time to accumulate. This Swiss company is flying under the radar but not for much longer I believe.
H
This company partnered years back with J and J and actually have very different pipeline. Suppose to be a read out soon.
D
Go Guys... One of the most shorted stock with low Float!
Bullish
T
What part of the game is this? Got in at $15.50 and thought I was doing something. Feels like it’s being held down. Might have to wait for AH
K
3 o’clock sour hour. Can it fill the gap?
Bearish
J
why no one buys this
H
What moving this today? Was going to add to this but had it for the last few years in foreign shares.
R
absolutely undervalued because of the current situation in the market.
B
Check out this youtube video that explains trading biotech stocks with decent strategies and explanations.
I wish I watched this years ago, it would have save me a lot of time.
Thu Jan 21 07:02:03 2021 EDT
First patient treated with ADX71149 (JNJ-40411813) scheduled for Q2 2021
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that its partner Janssen Pharmaceuticals, Inc. , part of the Janssen Pharmaceutical Companies of Johnson & Johnson , has received FDA’s Investigational New Drug (IND) approval to begin a Phase 2a proof of concept study with the selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM), JNJ-40411813 (ADX71149), in patients with epilepsy. The first patient is expected to be treated during Q2 2021.
Pre Market Resistance at 18.20 - then there is little resistance upwards.
I wish I watched this years ago, it would have save me a lot of time.
Enjoy
https://youtu.be/NPnKFYrib5Q